Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial - 26/07/22
, Jennifer R Brown, ProfMD e, Brad S Kahl, ProfMD f, Paolo Ghia, ProfMD g, Krzysztof Giannopoulos, ProfMD h, i, Wojciech Jurczak, ProfMD j, Martin Šimkovič, MD k, l, Mazyar Shadman, MD m, n, Anders Österborg, MD o, p, Luca Laurenti, ProfMD q, Patricia Walker, MBBS r, Stephen Opat, ProfMBBS s, t, Henry Chan, MBChB u, Hanna Ciepluch, PhD v, Richard Greil, ProfMD w, x, y, Monica Tani, MD z, Marek Trněný, ProfMD aa, Danielle M Brander, MD ab, Ian W Flinn, MD ac, Sebastian Grosicki, MD ad, Emma Verner, MBBS ae, af, Alessandra Tedeschi, MD ag, Jianyong Li, MD ah, Tian Tian, PhD ai, Lei Zhou, MD aj, Carol Marimpietri, RN ai, Jason C Paik, MD ai, Aileen Cohen, MD ai, Jane Huang, MD ai, Tadeusz Robak, ProfMD ak, †, Peter Hillmen, ProfMBChB al, †Summary |
Background |
Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine–rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL.
Methods |
We conducted an open-label, multicentre, phase 3 study at 153 academic or community hospitals in 14 countries and regions. Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on CLL criteria; were aged 65 years or older, or 18 years or older and had comorbidities; and had an Eastern Cooperative Oncology Group performance status score of 0–2. A central interactive web response system randomly assigned patients without del(17)(p13·1) to zanubrutinib (group A) or bendamustine–rituximab (group B) by sequential block method (permutated blocks with a random block size of four). Patients with del(17)(p13·1) were enrolled in group C and received zanubrutinib. Zanubrutinib was administered orally at 160 mg twice per day (28-day cycles); bendamustine at 90 mg/m2 of body surface area on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 of body surface area the day before or on day 1 of cycle 1, and 500 mg/m2 of body surface area on day 1 of cycles 2–6, were administered intravenously. The primary endpoint was progression-free survival per independent review committee in the intention-to-treat population in groups A and B, with minimum two-sided α of 0·05 for superiority. Safety was analysed in all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT03336333, and is closed to recruitment.
Findings |
Between Oct 31, 2017, and July 22, 2019, 590 patients were enrolled; patients without del(17)(p13·1) were randomly assigned to zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238). At median follow-up of 26·2 months (IQR 23·7–29·6), median progression-free survival per independent review committee was not reached in either group (group A 95% CI not estimable [NE] to NE; group B 28·1 months to NE). Progression-free survival was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 to 0·63]; two-sided p<0·0001). The most common grade 3 or worse adverse event was neutropenia (27 [11%] of 240 patients in group A, 116 [51%] of 227 in group B, and 17 [15%] of 111 patients in group C). Serious adverse events occurred in 88 (37%) of 240 patients in group A, 113 (50%) of 227 patients in group B, and 45 (41%) of 111 patients in group C. Adverse events leading to death occurred in 11 (5%) of 240 patients in group A, 12 (5%) of 227 patients in group B, and three (3%) of 111 patients in group C, most commonly due to COVID-19 (four [2%] of 240 patients in group A), diarrhoea, and aspiration pneumonia (two each [1%] of 227 patients in group B).
Interpretation |
Zanubrutinib significantly improved progression-free survival versus bendamustine–rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL.
Funding |
BeiGene.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 8
P. 1031-1043 - août 2022 Retour au numéro
Article précédent
- Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
- John M Pagel, Jacob D Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li, Andrew D Zelenetz
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
- Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Nelly Firmin, Pascaline Boudou-Rouquette, François Bertucci, Corinne Balleyguier, Valérie Lebrun-Ly, Isabelle Ray-Coquard, Elsa Kalbacher, Aurélie Bardet, Emmanuelle Bompas, Olivier Collard, Nicolas Isambert, Cécile Guillemet, Maria Rios, Baptiste Archambaud, Florence Duffaud, French Sarcoma Group, Antoine ITALIANO, Patricia PAUTIER, Axel LECESNE, Sophie PIPERNO-NEUMANN, Christine CHEVREAU, Didier CUPISSOL, Nicolas PENEL, Jérôme ALEXANDRE, François BERTUCCI, Isabelle RAY-COQUARD, Valérie LEBRUN-LY, Elsa KALBACHER, Florence DUFFAUD, Corinne DELCAMBRE, Emmanuelle BOMPAS, Olivier COLLARD, Nicolas ISAMBERT, Cécile GUILLEMET, Patrick SOULIE, Maria RIOS, Esma SAADA-BOUZID
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?